
|Videos|August 1, 2016
The Significance of the RESORCE Trial in HCC
Author(s)Bruno Daniele, MD
Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the significance of the RESORCE trial, which examined the use of regorafenib (Stivarga) as a treatment for patients with hepatocellular carcinoma (HCC).




















